318 research outputs found

    The Role of Policy in Facilitating Adoption of Climate-Smart Agriculture in Uganda

    Get PDF
    This study aimed at understanding the influence of policy frameworks on climate change adaptation in Uganda. It combined literature review on existing natural resource management policies, focus group discussions with farming communities and interviews with key informants across various policy implementation levels. Findings reveal that even when farmers are exposed to appropriate adaptation practices, adoption is still constrained by limited enforcement of policies and regulations. Various reasons constrain enforcement; policies are formulated through top–down approaches, NGOs and local governments are minimally involved while local communities are largely excluded. There is either lack of or existence of non-functional implementation structures prescribed by the policies. Coupled with unclear roles among actors, weak links between different administration levels, limited human and financial resources and political interference, the ability of smallholders to adopt climate-smart agriculture (CSA) is thus constrained. Due to lack of knowledge of what the policies provide for, smallholders are not able to demand their rights. There is need for more focused follow-up research on specific issues raised in this report

    Agronomic performance of local and introduced plantains, dessert, cooking and beer bananas (Musa spp.) across different altitude and soil conditions in eastern Democratic Republic of Congo

    Get PDF
    Open access Journal; Published: 27 October 2016Agronomic performances of local and exotic Musa species were evaluated across seven agro-ecologies in Eastern Democratic Republic of Congo. Generally, all the cultivars performed well. Mean bunch yields varied between 11 and 42 kg across different use groups and agro-ecologies. Introduced cultivars had higher or comparable yields to the local cultivars across agro-ecologies. The exotic beer cultivar ‘NARIAT 27’ generally outperformed other beer types. The green cooking exotic types ‘NARITA 4’ and ‘NARITA 2’ produced bunches of up to 37 and 39 kg, respectively at altitudes of 1066 and 1111 m, though having smaller bunches of 21 to 25 kg, at 900 and 1707 m in comparison to the local type ‘Barhabeshya’ (30 to 37 kg). Yields were mainly influenced by soil factors and altitude. Yields generally increased with increase in OM, N, P, K, Ca, and pH. Altitude had a non-linear relationship with the time from planting to flowering, with the time from planting to flowering declining at higher altitudes. In contrast, the fruit filling phase increased linearly with altitude. Bunch weights of most cultivars declined with increasing altitude; particularly, when N, K, P and OM concentrations were low; possibly because most assimilates go towards sucker development at the high altitudes. For example, bunch weights of ‘Barhabeshya’, ‘Mbwazirume’ and ‘Nshika’ strongly declined (R2 = -0.56-0.99) with increasing altitude. ‘Ndundu’, ‘FHIA21’ and ‘Gros Michel’ thrived well at high altitude sites. Such variations in cultivar adaptability plus cultivar attributes, e.g. height can be exploited by selectively promoting cultivars in specific agro-ecologies/niches

    Investigation of amphibian mortality events in wildlife reveals an on-going ranavirus epidemic in the North of the Netherlands

    Get PDF
    In the four years following the first detection of ranavirus (genus Ranavirus, family Iridoviridae) infection in Dutch wildlife in 2010, amphibian mortality events were investigated nationwide to detect, characterize and map ranaviruses in amphibians over time, and to establish the affected host species and the clinico-pathological presentation of the disease in these hosts. The ultimate goal was to obtain more insight into ranavirus disease emergence and ecological risk. In total 155 dead amphibians from 52 sites were submitted between 2011 and 2014, and examined using histopathology, immunohistochemistry, virus isolation and molecular genetic characterization. Ranavirus-associated amphibian mortality events occurred at 18 sites (35%), initially only in proximity of the 2010 index site. Specimens belonging to approximately half of the native amphibian species were infected, including the threatened Pelobates fuscus (spadefoot toad). Clustered massive outbreaks involving dead adult specimens and ranavirus genomic identity indicated that one common midwife toad virus (CMTV)-like ranavirus strain is emerging in provinces in the north of the Netherlands. Modelling based on the spatiotemporal pattern of spread showed a high probability that this emerging virus will continue to be detected at new sites (the discrete reproductive power of this outbreak is 0.35). Phylogenetically distinct CMTV-like ranaviruses were found in the south of the Netherlands more recently. In addition to showing that CMTV-like ranaviruses threaten wild amphibian populations not only in Spain but also in the Netherlands, the current spread and risk of establishment reiterate that understanding the underlying causes of CMTV-like ranavirus emergence requires international attention

    Scenario-guided policy planning in Uganda

    Get PDF
    Using socio-economic scenarios in policy formulation allows for an anticipatory approach to governance processes and the formulation of policies/plans that take into account future uncertainty To fully benefit from the dividends of scenario planning in the Ugandan context, there is need to build the scenario-guided planning capacity of both public and private sectors. There is need for follow up and continuous engagement with government officials responsible after the review process to enable inclusion of recommendations generated into the final policy documents. In some cases, the abstract nature of national policy statements limits the level of detail, hence detailed scenario guided recommendations and information may not easily fit in the existing policy formats. The approach is new and requires extra awareness creation not only for the government officers who draft policies but also for other major policy actors such as the political leadership who approve the policies

    Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration

    Get PDF
    PURPOSE: Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as treatment of neovascular age-related macular degeneration (nAMD), the (economic) burden on the healthcare system is considerable. A treat-and-extend (T&E) regimen is associated with a lower number of injections without compromising the effectiveness and can therefore help optimise nAMD treatment. This study investigates the per-patient costs associated with nAMD treatment, when using aflibercept, bevacizumab, or ranibizumab with a T&E regimen. METHODS: In this cost-minimisation model, the per-patient costs in the Netherlands were modelled using a healthcare payers’ perspective over a 3-year time horizon with the assumption that efficacy of treatments is similar. Additionally, the break-even price of the different anti-VEGFs was calculated relative to the cheapest option and injection frequency. RESULTS: The injection frequency varied from 14.2 for aflibercept to 27.4 for bevacizumab in 3 years. Nonetheless, bevacizumab remains the cheapest treatment option (€14,215), followed by aflibercept (€18,202) and ranibizumab (€31,048). The medication covers the majority of the per-patient costs for aflibercept and ranibizumab, while administration covers the majority of the per-patient costs for bevacizumab. The break-even prices of aflibercept and ranibizumab are respectively €507 and €60.58 per injection. Brolucizumab was included in the scenario analysis and was more expensive than aflibercept (€20,446). Brolucizumab should reduce to 13.8 injections over 3 years to be as costly as aflibercept. CONCLUSION: Bevacizumab is the cheapest anti-VEGF treatment. The list prices of all anti-VEGFs should reduce to be as costly as bevacizumab. Aflibercept is the second-choice treatment and so far brolucizumab is not
    • …
    corecore